MCS at the Forefront of Pandemics Management

It's not just covid-19: cross-border threats are a general issue

Brussels; Feb. 1, 2020. While the appearance of novel coronavirus covid-19 has dominated the headlines for months, epidemics always have been a cross-border threat. Last year already, the European Commission through its H2020 program issued a call for proposals on how to mitigate cross-border risks in epidemics. MCS, along with a large European consortium of research organizations, universities and companies, has now received approval from the Commission to conduct an innovative action.

The project, unrelated to covid-19, takes a long-term approach in addressing the underlying systemic cross border issues to deal with when it comes to pandemics. The European Commission in its continued effort to predict and manage pandemics is on the search for innovative solutions that tackle the issue regardless of a particular disease.

The innovative action with the title 'Demonstration of intelligent decision support for pandemic crisis prediction and management within and across European borders' (acronym: 'STAMINA') is a 24-month long action under the European H2020's innovation action topic 'demonstration of novel concepts for the management of pandemic crises'.

Suheib Mousa, the CEO of 7-year old MCS states: 'When we submitted this proposal to the European Commission, none of our team members thought pandemics would dominate each person's life around the world just a few months later. Now we know our technology can add to social good in the future.'

STAMINA envisions to better equip pandemic crises management practitioners at national and regional levels within and across EU borders to anticipate and respond to the 'known-unknowns' in their daily effort to enhance health security. This STAMINA vision is realized through a multi- and trans-disciplinary user-centric approach with various concrete technical, scientific and business objectives.

For this purpose, the consortium members will develop a technical ecosystem with the STAMINA engine being a core part. MCS will support in architectural system design, decision support toolset integration, point-of-care diagnostics and monitoring tools configuration, as well as the development of an interface for data exchange.

MCS' technology will include learnings from observations currently being made in managing the covid-19 crisis. The firm having strong expertise in smart wearables and Artificial Intelligence (AI), will play a crucial role in tracking epidemics and consequently also managing them. Shutting

borders already by now has been proven to create a huge negative impact on the global economy. MCS technology therefore can be used not only to pinpoint outbreak clusters and (i) help avoiding the spreading of such clusters, but also (ii) to help monitor the health condition of affected individuals. Says Suheib Mousa: 'In future, governments will aim to acquire technology that will minimize the collateral economic damage that we currently see in covid-19'.

The consortium consists of 38 first responders, government agencies, research organizations, universities, and other entities from 17 European or associated countries. The project is funded by the European Commission with a budget of EUR 9.5 million (grant agreement ID: 883441).

For further information, contact:

MCS Data Labs GmbH
Bismarckstr. 10-12
10625 Berlin
Germany

:phone +49 30 59 00 83 280
:fax +49 30 59 00 83 208
info@mcs-datalabs.com
www.mcs-datalabs.com

About MCS Data Labs

MCS Data Labs, a privately owned technology firm in Berlin (Germany), is predominantly engaged in hardware and software for digital health and public safety. Main competencies of the company include wearable technologies, Artificial intelligence, IoT and machine learning. The SME is consortium member in several large European research and innovation projects that focus on cancer, motion detection, diabetes and pandemic management. Flagship project is its proprietary SmarKo® Health ecosystem for remote patient monitoring. CEO is Suheib Mousa.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 883441